(Total Views: 404)
Posted On: 03/19/2021 10:32:27 AM
Post# of 151579
Re: chazzledazzle #83589
“Wouldn't you agree, that Leronlimab would be wasted in the early, viral stages of Sars-CoV-2 infection? And more useful in the immune-deficient stages of the Covid-19 disease?”
You completely missed the point as the post was about NP misleading investors.
NEWS2 was reduced in the M2M trial and I suspect a larger trial would show the same. Therefore, leronlimab could be valuable in reducing progression to S/C if given early in the disease to those who are most at risk.
You completely missed the point as the post was about NP misleading investors.
NEWS2 was reduced in the M2M trial and I suspect a larger trial would show the same. Therefore, leronlimab could be valuable in reducing progression to S/C if given early in the disease to those who are most at risk.
(2)
(0)Scroll down for more posts ▼
